www.fdanews.com/articles/196217-takeda-to-develop-coronavirus-treatment
![Test Tubes, computer Screen, testing](https://www.fdanews.com/ext/resources/test/Drug-Images4/test-tubes-computer-screens.gif?t=1584050488&width=430)
Takeda to Develop Coronavirus Treatment
March 12, 2020
Takeda Pharmaceuticals said it will develop a plasma-derived therapy for patients infected with coronavirus.
The drugmaker said it will be developing an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, while also looking into other products it is developing or marketing that can treat infected patients.
Hyperimmune globulins are plasma derived-therapies that have previously been shown effective for treating severe acute viral respiratory infections.